Pfizer/Hospira's Biosimilar Pipeline: Substantial Overlap, Limited Divestiture So Far
This article was originally published in The Pink Sheet Daily
Executive Summary
All five biosimilars in Pfizer’s clinical pipeline overlap with those in Hospira’s, but even though only infliximab is required to be divested, the others could also be sold off to reach cost-saving targets.
You may also be interested in...
Pfizer Not Making Pricing Changes, Sees Ways To Work With Trump
Pfizer CEO Ian Read said during the company’s quarterly call that there are ‘lots of ways’ to work with the new Trump administration, his comments coming on the same day several industry leaders met with the new US president.
Pfizer's Herceptin Biosimilar Moving Forward Amid Rising Competition
Pfizer hopes positive top-line Phase III trial data on its Herceptin (trastuzumab) biosimilar can help it tap the lucrative market in HER2-overexpressing cancers, but analysts say that therapeutic space looks increasingly crowded with no clear favorite yet in sight.
Pfizer's Herceptin Biosimilar Moving Forward Amid Rising Competition
Pfizer hopes positive top-line Phase III trial data on its Herceptin (trastuzumab) biosimilar can help it tap the lucrative market in HER2-overexpressing cancers, but analysts say that therapeutic space looks increasingly crowded with no clear favorite yet in sight.